FDA grants accelerated approval of Breyanzi for Follicular Lymphoma treatment
USA—The FDA recently granted accelerated approval for Bristol Myers Squibb’s Breyanzi to treat...
Read More
Tag: Bristol Myers Squibb
Bristol Myers Squibb teams up with Cellares to boost CAR-T manufacturing
USA—Bristol Myers Squibb, a renowned American biopharmaceutical company, has formed a strategic...
Read More
FDA approves Breyanzi, a new CAR-T cell therapy for blood cancers
USA—The Food and Drug Administration of the United States has approved Breyanzi, a cell therapy...
Read More
Bristol Myers Squibb adjusts sales projections as challenges loom
USA — Bristol Myers Squibb, a prominent pharmaceutical company, has recalibrated its sales...
Read More
Bristol Myers Squibb to acquire Mirati Therapeutics, bolstering oncology portfolio
USA — Bristol Myers Squibb has entered into an agreement to acquire Mirati Therapeutics for US$4.8...
Read More
BMS and Evotec forge enhanced neurology alliance, now valued at US$4 Billion
USA — Pharmaceutical company Bristol-Myers Squibb (BMS) has once again expanded its collaboration...
Read More
Pricing hurdles force Bristol Myers to abandon plans for launching new cancer drug in Germany
GERMANY — Bristol Myers Squibb, following its European approval last September, has announced that...
Read More
Bristol Myers buys Turning Point Therapeutics for US$4B, strikes up Roche rivalry
UNITED KINGDOM – Bristol Myers Squibb has acquired Turning Point Therapeutics in a US$4.1 billion...
Read More
FDA approves Bristol Myers’ immunotherapy for advanced melanoma
USA – Bristol-Myers Squibb (BMS) announced that the first drug in a new class of cancer...
Read More
BMS faces competition as Teva launches first Revlimid generic in US
USA – Teva has launched its generic version of Bristol Myers Squibb’s Revlimid...
Read More
LATEST DIGITAL MAGAZINE
